Experienced in Ovarian Cancer

Romain Rivoirard

CHU De Saint Etienne
Saint-etienne-de-valoux, FR 
Experienced in Ovarian Cancer
CHU De Saint Etienne
Saint-etienne-de-valoux, FR 
OverviewLocationsClinical Research

Overview

Romain Rivoirard practices in Saint-etienne-de-valoux, France. Mr. Rivoirard is rated as an Experienced expert by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Oligodendroglioma, Glioma, Astrocytoma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Ovarian Cancer.

Gender
Male

Locations

CHU de Saint Etienne
Saint-etienne-de-valoux, France
Other Locations
Saint-priest-la-vetre, France
108 Bis, Avenue Albert Raimond, BP60008, 42271 Saint Priest En Jarez Cedex, EMR3738, Oullins, 69921, France
St. Priest En Jarez Cedex, France
St Priest En Jarez Cedex, Sete, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway
Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Enrollment Status: Completed
Publish Date: April 04, 2022
Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Enrollment Status: Terminated
Publish Date: December 30, 2021
Intervention Type: Drug
Study Drug: Optimal TURB
Study Phase: Phase 2
CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Enrollment Status: Completed
Publish Date: September 10, 2021
Intervention Type: Drug
Study Phase: Phase 2
Description the Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia : Prospective Descriptive Non-comparative Cohort ( QUALI Cohort)
Description the Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia : Prospective Descriptive Non-comparative Cohort ( QUALI Cohort)
Enrollment Status: Terminated
Publish Date: July 07, 2020
Intervention Type: Other
View 5 Less Clinical Trials

55 Total Publications

Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Journal: Neuro-oncology advances
Published: June 10, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rivoirard's expertise for a condition
ConditionClose
        View All 19 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile